| Market Cap | 97.35M | P/E | - | EPS this Y | 44.30% | Ern Qtrly Grth | - |
| Income | -73.79M | Forward P/E | -1.26 | EPS next Y | -19.40% | 50D Avg Chg | -12.00% |
| Sales | - | PEG | -0.12 | EPS past 5Y | - | 200D Avg Chg | 8.00% |
| Dividend | N/A | Price/Book | 0.60 | EPS next 5Y | 34.60% | 52W High Chg | -64.00% |
| Recommedations | 1.40 | Quick Ratio | 4.63 | Shares Outstanding | 58.89M | 52W Low Chg | 125.00% |
| Insider Own | 19.85% | ROA | -26.10% | Shares Float | 38.70M | Beta | 1.45 |
| Inst Own | 38.37% | ROE | -51.51% | Shares Shorted/Prior | 1.85M/2.70M | Price | 2.47 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 390,661 | Target Price | 8.83 |
| Oper. Margin | - | Earnings Date | Aug 11 | Volume | 151,411 | Change | -3.89% |
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
| HC Wainwright & Co. | Buy | May 16, 24 |
| HC Wainwright & Co. | Buy | Apr 10, 24 |
| RBC Capital | Outperform | Mar 22, 24 |
| HC Wainwright & Co. | Buy | Mar 22, 24 |
| BTIG | Buy | Feb 9, 24 |
| Leerink Partners | Outperform | Jan 23, 24 |
| HC Wainwright & Co. | Buy | Nov 30, 23 |
| RBC Capital | Outperform | Sep 5, 23 |
| EF Hutton | Buy | Jul 31, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Wadhane Jitendra | Chief Accounting Off.. Chief Accounting Officer | Sep 27 | Buy | 1.87 | 2,500 | 4,675 | 226,937 | 09/27/23 |
| Connealy Pamela Ann | CFO and COO CFO and COO | Sep 27 | Buy | 1.8468 | 6,426 | 11,868 | 810,532 | 09/27/23 |
| Wadhane Jitendra | Chief Accounting Off.. Chief Accounting Officer | Sep 25 | Buy | 1.77 | 5,000 | 8,850 | 224,437 | 09/25/23 |
| Connealy Pamela Ann | CFO and COO CFO and COO | Sep 25 | Buy | 1.6703 | 12,000 | 20,044 | 804,106 | 09/25/23 |
| Wadhane Jitendra | Chief Accounting Off.. Chief Accounting Officer | Sep 22 | Buy | 1.7397 | 2,500 | 4,349 | 219,437 | 09/22/23 |
| Connealy Pamela Ann | CFO and COO CFO and COO | Sep 22 | Buy | 1.739 | 5,000 | 8,695 | 792,106 | 09/22/23 |
| Sullivan Lara | President and CEO President and CEO | Sep 14 | Sell | 2.18 | 8,641 | 18,837 | 2,403,882 | 09/18/23 |
| Sullivan Lara | President and CEO President and CEO | Sep 11 | Sell | 2.26 | 27,917 | 63,092 | 2,597,265 | 09/13/23 |
| PFIZER INC | 10% Owner 10% Owner | Mar 17 | Buy | 2.76 | 1,811,594 | 4,999,999 | 5,952,263 | 03/21/23 |
| Chin Mark | Other Other | Apr 21 | Sell | 3.05 | 1,745,761 | 5,324,571 | 04/25/22 | |
| Chin Mark | Director Director | Oct 13 | Buy | 16 | 312,500 | 5,000,000 | 1,745,761 | 10/15/21 |